Is everything known in all faces of iceberg in PRAME?

Leukemia Research

Volumn 32, Issue 9, 2008, Pages 1356-1357

  Paydas, Semra ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Immunotherapy; MDR induction; Minimal residual disease; PRAME; Targeting PRAME

Indexed keywords

CANCER TESTIS ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST TUMOR; CANCER IMMUNOTHERAPY; EDITORIAL; GENE; GENE EXPRESSION; HUMAN; LEUKEMIA; LYMPHOMA; MEDULLOBLASTOMA; MELANOMA; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; NEPHROBLASTOMA; PRAME GENE; PRIORITY JOURNAL; PROGNOSIS; SOFT TISSUE SARCOMA;

ANTIGENS, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, HAIRY CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; TUMOR MARKERS, BIOLOGICAL;

EID: 43049170335     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.02.024     Document Type: Editorial

References (22)

1. Ikeda H., Lethe B., Lehmann F., van Baren N., Baurain J., De Semet C., et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6 (1997) 199-208
2. Ikeda H., Matsushita M., and Kawakami H. PRAME protein expressed in leukemia cells as a target molecule for immunotherapy. Rinsho Ketsueki 40 (1999) 484-486
3. Tajeddine N., Gala J.L., Louis M., Schoor M.V., Tombal B., and Gailly P. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res 65 (2005) 7348-7355
4. Goellner S., Steinbach D., Schenk T., Gruhn B., Zintl F., Ramsay E., et al. Childhood acute myelogenous leukaemia: association between PRAME, apoptosis- and MDR-related gene expression. Eur J Cancer 42 (2006) 2807-2814
5. Epping M.T., Wang L., Edel M.J., Carlee L., Hernandez M., and Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122 (2005) 835-847
6. Proto-Siqueira R., Figueiredo-Pontes L.L., Panepucci R.A., Aglair B., Garcia R.A., Rizzatti E.G., et al. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res 30 (2006) 1333-1339
7. van Baren N., Brasseur F., Godelaine D., Hames G., Ferrant A., Lehmann F., et al. Genes encoding tumor specific antigens are expressed in human myeloma cells. Blood 94 (1999) 1156-1164
8. Greiner J., Schmitt M., Li L., Giannopoulos K., Bosch K., Schmitt A., et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 108 (2006) 4109-4117
9. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
10. Oberthuer A., Hero B., Spitz R., Berthold F., and Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 10 (2004) 4307-4313
11. Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O'Driscoll L. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat July 12, 2007 [Epub ahead of print].
12. van Baren N., Chambost H., Ferrant A., Michaux L., Ikeda H., Millard I., et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells is expressed in acute leukemia cells. Br J Haematol 102 (1998) 1376-1379
13. Greiner J., Ringhoffer M., Simikopinko O., Szmaragowska A., Huebsch S., Maurer U., et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol 28 (2000) 1413-1422
14. Matsushita M., Ikeda H., Kizaki M., Okamoto S., Ogasawara M., Ikeda Y., et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haemtol 112 (2001) 916-926
15. Paydas S., Tanriverdi K., Yavuz S., Disel U., Baslamisli F., and Burgut R. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol 79 (2005) 257-261
16. Steinbach D., Hermann J., Viehmann S., Zintl F., and Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 133 (2002) 118-123
17. Ismael S.J., Zago M.A., Proto-Siqueira R., Falcão R.P., and Souza C.A. The expression of PRAME in chronic lymphoproliferative disorders. Leuk Res 27 (2003) 393-396
18. Paydas S., Tanriverdi K., Yavuz S., and Seydaoglu G. PRAME mRNA levels in cases with chronic leukemia: clinical importance and review of the literature. Leuk Res 31 (2007) 365-369
19. Arons E., Suntum T., Margulies I., Yuan C., Stetler-Stevenson M., and Kreitman R.J. PRAME expression in hairy cell leukemia. Leuk Res. 32 (2008) 1400-1406
20. Lethe B., van der Bruggen P., Brasseur F., and Boon T. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Res 7 Suppl. 2 (1997) S83-S88
21. Matsushita M., Yamazaki R., Ikeda H., and Kawakami Y. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies. Leuk Lymphoma 44 (2003) 439-444
22. Tajeddine N., Millard I., Gailly P., and Gala J.L. Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin Chem Lab Med 44 (2006) 548-555